The primary purpose of this study is to measure the response rate in participants with the
myeloproliferative neoplasms (MPNs), polycythemia vera (PV), essential thrombocythemia (ET),
or myelofibrosis (MF) when treated with LY2784544, including those who have demonstrated an
intolerance to, failure of primary response to, or have demonstrated disease progression
while on ruxolitinib.